Polaryx Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Polaryx Therapeutics, Inc. (PLYX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$1.38 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-13
- Polaryx Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$1.38M.
- Polaryx Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$2.54M.
- Polaryx Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$1.01M.
- Polaryx Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$5.05M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month |
|---|---|---|
| 2026-06-30 | -$1.38M 10-Q · filed 2026-08-13 | -$3.92M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$2.54M 10-Q · filed 2026-05-15 | |
| 2025-06-30 | -$1.01M 10-Q · filed 2026-08-13 | -$6.06M 10-Q · filed 2026-08-13 |
| 2025-03-31 | -$5.05M 10-Q · filed 2026-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |